|Mnemonic: ||[Unlist Lab]|
|Name: ||BCR-ABL1 Mutation Analysis for Tyrosine Kinase Inhibitor Resistance by Next Generation Sequencing|
|Specimen: ||5 mL whole blood from a Lavender top tube. or 3 mL bone marrow.|
Include information regarding any current kinase inhibitor treatment the patient may be receiving.
Clotted samples are unacceptable.
Ambient/frozen samples are unacceptable.
Plasma and serum are unacceptable.
|Minimum Spec: ||1 mL|
|Transport Temp: ||Refrigerated|
|Spec Stability: ||Stable 48 hours refrigerated.|
|Ref Lab/Code: ||ARUP 2008420|
| Method: ||Massive Parallel Sequencing|
|Note: ||Order only for patients with an established diagnosis of a BCR-ABL1 positive leukemia. This test is used to determine if a mutation is present that would interfere with response to TKI therapy in Philadelphia chromosome positive (Ph+) lymphoblastic leukemia or chronic myelogenous leukemia (CML). The test detects all common mutations, including T315I. For initial BCR-ABL1 testing, refer to the reflex test (2005010).|